On November 4, 2019 Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, reported that Immunomic scientists will present data from its oncology programs at the following scientific and medical conferences (Press release, Immunomic Therapeutics, NOV 4, 2019, View Source [SID1234550266]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data to be presented at the conferences will show the broad promise of Immunomics’ pipeline and the productivity of our UNITE proprietary technology platform," said Dr. Teri Heiland, Chief Scientific Officer. "We are committed to advancing our research into the clinic for patients in the years ahead."

Upcoming Medical & Scientific Conferences:

SITC (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)) 34th Annual Meeting
Title: Lysosomal-associated membrane protein-1-targeting of a poly-neoepitope DNA vaccine elicits potent immune responses and inhibits tumor growth
Presentation Date: Saturday, November 9th 7:00 am – 8:30 pm Eastern Time
Location: Poster Hall (Prince George AB), Gaylord National Hotel and Convention Center, National Harbor, Maryland
International Conference on Vaccines Research & Development
Title: Rapid activation of antigen-specific CD4 T cells by HER2-UNITE therapeutic vaccine suppresses tumor growth and prolongs survival
Presentation Date: Tuesday, November 19th at 10:55 a.m. – 11:20 a.m. Eastern Time
Location: Session-I Cancer Vaccines | Immunotherapy & Immunodominance, HALL-A, Crowne Plaza Boston, Newton, Boston
2019 Society for Neuro-Oncology Annual Meeting
Title: CMV-Based Plasmid DNA Vaccine for GBM Using the UNITE Platform
Presentation Date: Friday November 22, 2019 at 4:30 p.m. Eastern Time
Location: Concurrent Session 2C: Drug Discovery/Drug Resistance and Experimental Therapeutics (2C), JW Marriott Desert Ridge, Phoenix, Arizona